Literature DB >> 14601095

Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma.

Yuki Morimoto1, Toshifumi Ozaki, Mamoru Ouchida, Norifumi Umehara, Norihide Ohata, Aki Yoshida, Kenji Shimizu, Hajime Inoue.   

Abstract

BACKGROUND: A recent study revealed that single nucleotide polymorphism (SNP) at codon 388 (Gly or Arg) of fibroblast growth factor receptor 4 (FGFR4) was associated with prognosis in patients with carcinoma of the breast and colorectal carcinoma. The purpose of the current study was to investigate the correlation between codon 388 SNP and clinical prognosis in patients with sarcoma of the bone and soft tissues.
METHODS: Tumor samples were obtained from 143 patients with high-grade bone and soft tissue sarcomas at Okayama University Hospital between 1986-2002, and from 102 healthy volunteers. SNP of codon 388 was detected by sequencing and fragment length of polymerase chain reaction products digested by restriction enzyme. The chi-square test was used to compare genotype distribution and the Kaplan-Meier method was used for survival analysis.
RESULTS: With regard to FGFR4 genotypes in the 143 patients studied, 54 (37.8%) were Gly/Gly, 72 (50.3%) were Gly/Arg, and 17 (11.9%) were Arg/Arg, findings that were not significantly different from those of controls (P = 0.97). With regard to cumulative overall and metastasis-free survival, patients with the Gly/Gly genotype were found to have a better prognosis (P = 0.085 and P = 0.27, respectively). FGFR4 SNP was found to be correlated significantly with overall and metastasis-free survival in patients with soft tissue sarcomas (P = 0.029 and P = 0.045, respectively), but not in those patients with bone sarcomas (P = 0.88 and P = 0.75, respectively).
CONCLUSIONS: In the current study, the authors found a significant correlation between FGFR4 SNP and prognosis in patients with soft tissue sarcoma, although the samples were comprised of various histologic types. This SNP might be used to improve the prediction of clinical prognosis and lead to new treatment strategies in patients with soft tissue sarcomas. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14601095     DOI: 10.1002/cncr.11778

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  33 in total

Review 1.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

Authors:  Kevin M Levine; Kai Ding; Lyuqin Chen; Steffi Oesterreich
Journal:  Pharmacol Ther       Date:  2020-05-31       Impact factor: 12.310

Review 2.  Review: Single nucleotide polymorphisms associated with the oncogenesis of colorectal cancer.

Authors:  Koshi Mimori; Fumiaki Tanaka; Kohei Shibata; Masaki Mori
Journal:  Surg Today       Date:  2011-11-30       Impact factor: 2.549

3.  FGFR-4 Arg³⁸⁸ enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling.

Authors:  Wendong Yu; Shu Feng; Olga Dakhova; Chad J Creighton; Yi Cai; Jianghua Wang; Rile Li; Anna Frolov; Gustavo Ayala; Michael Ittmann
Journal:  Clin Cancer Res       Date:  2011-05-27       Impact factor: 12.531

4.  Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients.

Authors:  Yan-Ying Shen; Ya-Chao Lu; Dan-Ping Shen; Yuan-Jie Liu; Xin-Ying Su; Guan-Shan Zhu; Xiao-Lu Yin; Xing-Zhi Ni
Journal:  World J Gastroenterol       Date:  2013-07-28       Impact factor: 5.742

5.  The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes.

Authors:  Shereen Ezzat; Lei Zheng; Jose C Florez; Norbert Stefan; Thomas Mayr; Maw Maw Hliang; Kathleen Jablonski; Maegan Harden; Alena Stančáková; Markku Laakso; Hans-Ulrich Haring; Axel Ullrich; Sylvia L Asa
Journal:  Cell Metab       Date:  2013-06-04       Impact factor: 27.287

6.  Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression.

Authors:  Jianghua Wang; Wendong Yu; Yi Cai; Chengxi Ren; Michael M Ittmann
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

Review 7.  Factors underlying sensitivity of cancers to small-molecule kinase inhibitors.

Authors:  Pasi A Jänne; Nathanael Gray; Jeff Settleman
Journal:  Nat Rev Drug Discov       Date:  2009-07-24       Impact factor: 84.694

8.  Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis.

Authors:  Natacha Entz-Werle; Thomas Lavaux; Nadia Metzger; Corinne Stoetzel; Christelle Lasthaus; Perrine Marec; Chantal Kalifa; Laurence Brugieres; Hélène Pacquement; Claudine Schmitt; Marie-Dominique Tabone; Jean-Claude Gentet; Patrick Lutz; Annie Babin; Pierre Oudet; Marie Pierre Gaub; Fabienne Perrin-Schmitt
Journal:  Neoplasia       Date:  2007-08       Impact factor: 5.715

9.  Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcoma.

Authors:  Bridget Charbonneau; Rachel Isaksson Vogel; J Carlos Manivel; Anthony Rizzardi; Stephen C Schmechel; Simona Ognjanovic; Subbaya Subramanian; David Largaespada; Brenda Weigel
Journal:  Hum Pathol       Date:  2013-05-10       Impact factor: 3.466

10.  Germline variant FGFR4  p.G388R exposes a membrane-proximal STAT3 binding site.

Authors:  Vijay K Ulaganathan; Bianca Sperl; Ulf R Rapp; Axel Ullrich
Journal:  Nature       Date:  2015-12-16       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.